Seminars in Oncology
Volume 33, Supplement 3 , Pages 26-32, February 2006

Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms

  • Reinhard Dummer

      Affiliations

    • University Hospital of Zurich, Switzerland
    • Corresponding Author InformationAddress correspondence and reprint requests to Reinhard Dummer, MD, Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland
  • ,
  • Francine Foss

      Affiliations

    • Yale Center, New Haven, CT
  • ,
  • Brigitte Dreno

      Affiliations

    • Unit of Skin Oncology, Nantes, France
  • ,
  • Martine Bagot

      Affiliations

    • Paris 12 University, Paris, France

There are now a wide variety of therapeutic options for managing patients with cutaneous T-cell lymphoma-related symptoms. These include skin-directed therapies such as psoralen with UVA irradiation (PUVA), topical chemotherapies such as mechlorethamine (nitrogen mustard) and carmustine (BCNU), electron beam radiation, and systemic therapies such as chemotherapy, photopheresis, and interferons. Although treatment algorithms exist for patients with early stage disease, often treatments are individualized, based on patient specific factors, cost, and accessibility of referral centers for specialized therapies. This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

 Prof Foss is a member of the speakers’ bureau for Ligand Pharmaceuticals. Prof Bagot has served as a consultant to Zeneus. Prof Dummer has participated in scientific symposia and advisory boards sponsored by Zeneus and Ligand Pharmaceuticals.

PII: S0093-7754(05)00514-2

doi:10.1053/j.seminoncol.2005.12.020

Seminars in Oncology
Volume 33, Supplement 3 , Pages 26-32, February 2006